(NASDAQ: BPMC) Blueprint Medicines's forecast annual revenue growth rate of 28.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Blueprint Medicines's revenue in 2025 is $562,120,000.On average, 9 Wall Street analysts forecast BPMC's revenue for 2025 to be $46,398,021,693, with the lowest BPMC revenue forecast at $45,782,941,172, and the highest BPMC revenue forecast at $47,164,353,639. On average, 9 Wall Street analysts forecast BPMC's revenue for 2026 to be $62,238,734,633, with the lowest BPMC revenue forecast at $59,945,163,697, and the highest BPMC revenue forecast at $65,447,563,984.
In 2027, BPMC is forecast to generate $77,568,925,576 in revenue, with the lowest revenue forecast at $74,532,982,675 and the highest revenue forecast at $80,874,305,260.